In the ever-evolving field of cancer research, protein biomarkers play a pivotal role in the detection, diagnosis, and treatment of this complex disease. Utilizing antibodies to measure the expression levels of these proteins provides invaluable insights for the early detection, diagnosis, prognosis/monitoring, and treatment of specific cancers, transforming the landscape of oncology research.
In the laboratory and clinic, Western blots, flow cytometry, co-immunoprecipitation (co-IP), ELISA, and immunohistochemistry (IHC) are routinely employed to analyze protein expression levels of existing biomarkers and for the discovery and validation of new ones. IHC, in particular, is a powerful technique for visualizing the presence, localization, and quantity of specific biomarkers within tissue samples. This technique is widely used in cancer research and to validate potential biomarkers.
NeoBiotechnologies offers a comprehensive portfolio of high-quality IHC antibodies targeting a vast array of cancer biomarkers, allowing you to explore diverse avenues in your research. Our antibodies are rigorously validated to ensure high specificity, minimizing false positives and enhancing the reliability of your results. Furthermore, our team of experts is dedicated to providing exceptional customer support, assisting you in finding the right antibodies for your specific research requirements.